12:00 AM
Jun 15, 2015
 |  BC Week In Review  |  Clinical News  |  Clinical Status

514G3: Phase I/II started

XBiotech began a double-blind, placebo-controlled, dose-escalation Phase I/II trial to evaluate 3 dose levels of 514G3 in combination with standard IV antibiotic...

Read the full 87 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >